Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal group C conjugate vaccine (Baxter International Inc.)
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MenC-TT vaccine, marketed under the brand name **NeisVac-C**, is a monovalent meningococcal group C conjugate vaccine used for active immunization against invasive disease caused by *Neisseria meningitidis* serogroup C. The vaccine consists of the capsular polysaccharide of serogroup C meningococci covalently linked to a **tetanus toxoid (TT)** carrier protein. This conjugation converts the polysaccharide from a T-cell independent to a T-cell dependent antigen, thereby enhancing immunogenicity and inducing immunological memory, particularly in infants and young children. Originally developed by **Baxter Innovations GmbH** and subsequently acquired by **Pfizer**, the vaccine is administered via intramuscular injection. It has been evaluated in clinical trials for safety and immunogenicity when administered alone or concomitantly with other pediatric vaccines, such as pneumococcal conjugate vaccines (e.g., PCV7).
- Brand names
- NeisVac-C
- Other names
- MenC-TT vaccinemeningococcal group C tetanus toxoid conjugate vaccineMenC-TT
02
Targets
Neisseria meningitidis group C capsular polysaccharideTT (Tetanus toxoid)
Beyond the preview
Go deeper on meningococcal group C conjugate vaccine (Baxter International Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal group C conjugate vaccine (Baxter International Inc.).